This first installment observes how the adjuvant treatment landscape has evolved for patients with HR+/HER2- early breast cancer, including discussion on the monarchE study.
Medical and Administrative Director of SCCA Community Sites
Medical Director, SCCA Affiliate Network
Clinical Professor of Medicine, University of Washington